Blog
RSS FeedPosted by Michael Wonder on 21 Jan 2023
Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it.
17 January 2023 - Two congressional committees recently released damning results of an 18 month investigation into the FDA’s approval of ...
Posted by Michael Wonder on 10 Jan 2023
Moderna considers price of $110-$130 for COVID-19 vaccine
9 January 2023 - Commercial price is similar to Pfizer’s plans for after government contracting ends. ...
Posted by Michael Wonder on 07 Jan 2023
Eisai's approach to US pricing for Leqembi (lecanemab), a treatment for early Alzheimer's disease, sets forth out concept of "societal value of medicine" in relation to "price of medicine"
6 January 2023 - Maximising our value for all stakeholders while giving back value to society. ...
Posted by Michael Wonder on 06 Jan 2023
US new drug price exceeds $200,000 median in 2022
5 January 2023 - After setting record high US prices in the first half of 2022, drug makers continued to ...
Posted by Michael Wonder on 30 Nov 2022
How CSL priced the world’s most expensive drug
1 December 2022 - When blood products giant CSL announced last week it had been given US regulatory approval for ...
Posted by Michael Wonder on 21 Nov 2022
Big pharma may have to reveal government deals in WHO's draft pandemic rules
17 November 2022 - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make ...
Posted by Michael Wonder on 11 Nov 2022
EQRx no longer seeks to disrupt prices in non-small-cell lung cancer space
10 November 2022 - The biotechnology company EQRx no longer seeks to disrupt prices in the non-small-cell lung cancer space. ...
Posted by Michael Wonder on 21 Oct 2022
Pfizer COVID vaccine price hike to boost revenue for years, rivals may follow
21 October 2022 - Pfizer's plan to as much as quadruple US prices for its COVID-19 vaccine next year is ...
Posted by Michael Wonder on 10 Feb 2022
Eli Lilly promises 40% discount for Innovent’s PD-1 in last-ditch bid to shift FDA review to drug pricing
10 February 2022 - Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics partnered PD-1 ...
Posted by Michael Wonder on 21 Aug 2021
Competition, consolidation and evolution in the pharmacy market
12 August 2021 - Implications for efforts to contain drug prices and spending. ...
Posted by Michael Wonder on 31 Jul 2021
FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?
29 July 2021 - In a long-awaited move, the FDA has approved the first so-called interchangeable biosimilar version of insulin, ...
Posted by Michael Wonder on 24 Jun 2021
Biogen expects slow Alzheimer’s drug uptake, may reset price
24 June 2021 - Company faces uproar over $56,000 a year price tag for Aduhelm. ...
Posted by Michael Wonder on 13 Jun 2021
Unaffordable treatment for severe malaria highlights U.S. drug market pitfalls
11 June 2021 - When Eli Lilly announced in 2017 that it would stop producing quinidine, it was the only ...
Posted by Michael Wonder on 08 Jun 2021
Biogen faces tough questions over $56,000 a year price of newly approved Alzheimer’s drug
8 June 2021 - The biotech company’s price for the drug is higher than the $10,000 to $25,000 some Wall Street ...
Posted by Michael Wonder on 08 Jun 2021
Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years
7 June 2021 - Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year ...